By By Cade Hildreth, BioInformant
Palo Alto, CA – Greenstone Biosciences, Inc. (“Greenstone Bio”), a commercial-stage computational biology company, announces that the Company has received a DISC0 grant funding from the California Institute of Regenerative Medicine (CIRM).
Greenstone Bio (Stanford Research Park) focuses on clinical genomics, human induced pluripotent stem cell (iPSC) technology, artificial intelligence / machine learning (AI/ML), and drug development. The Company has extensive knowledge and expertise in generating patient-derived iPSCs. The Company currently possesses the largest patient-derived iPSC Biobank and offering cell lines to academic collaborators at no cost.
This CIRM grant will allow Greenstone Bio to perform pre-clinical studies on genetic cardiovascular diseases. Greenstone Bio’s investigators will use AI/ML approaches to drug screening and drug discovery. Furthermore, Greenstone Bio will validate compounds for safety and efficacy using iPSC-derived cardiovascular cells from disease and healthy patients to fast-track drug discovery.